LT1919465T - Gsk-3 inhibitoriai - Google Patents

Gsk-3 inhibitoriai

Info

Publication number
LT1919465T
LT1919465T LTEP06776492.8T LT06776492T LT1919465T LT 1919465 T LT1919465 T LT 1919465T LT 06776492 T LT06776492 T LT 06776492T LT 1919465 T LT1919465 T LT 1919465T
Authority
LT
Lithuania
Prior art keywords
gsk
inhibitors
Prior art date
Application number
LTEP06776492.8T
Other languages
English (en)
Inventor
Ana Martinez Gil
Miguel Medina Padilla
Mercedes Alonso Cascon
Ana Fuertes Huerta
Maria Luisa Navarro Rico
Maria José Pérez Puerto
Ana Castro Morera
Ester Martin Aparicio
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of LT1919465T publication Critical patent/LT1919465T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
LTEP06776492.8T 2005-07-29 2006-07-28 Gsk-3 inhibitoriai LT1919465T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05380176A EP1749523A1 (en) 2005-07-29 2005-07-29 GSK-3 inhibitors
PCT/EP2006/007520 WO2007017145A2 (en) 2005-07-29 2006-07-28 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
LT1919465T true LT1919465T (lt) 2018-04-10

Family

ID=35445902

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP06776492.8T LT1919465T (lt) 2005-07-29 2006-07-28 Gsk-3 inhibitoriai

Country Status (24)

Country Link
US (1) US8686042B2 (lt)
EP (2) EP1749523A1 (lt)
JP (1) JP5484726B2 (lt)
KR (1) KR101471999B1 (lt)
CN (1) CN101257900B (lt)
AU (1) AU2006278829B2 (lt)
BR (1) BRPI0615968B1 (lt)
CA (1) CA2616451C (lt)
CY (1) CY1119971T1 (lt)
DK (1) DK1919465T3 (lt)
ES (1) ES2661326T3 (lt)
HK (1) HK1124761A1 (lt)
HR (1) HRP20180109T1 (lt)
HU (1) HUE036844T2 (lt)
IL (1) IL189048A (lt)
LT (1) LT1919465T (lt)
NO (1) NO341454B1 (lt)
NZ (1) NZ566380A (lt)
PL (1) PL1919465T3 (lt)
PT (1) PT1919465T (lt)
RU (1) RU2449998C2 (lt)
SI (1) SI1919465T1 (lt)
WO (1) WO2007017145A2 (lt)
ZA (1) ZA200800983B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5406030B2 (ja) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
AU2009211300A1 (en) * 2008-02-06 2009-08-13 Noscira, S.A. Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5756011B2 (ja) * 2008-04-24 2015-07-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
KR101702609B1 (ko) 2009-06-17 2017-02-03 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2013173206A1 (en) * 2012-05-14 2013-11-21 University Of Kansas Phosphonate derivatives for treatment of alzheimer's disease
KR102168088B1 (ko) 2013-03-14 2020-10-20 더 브리검 앤드 우먼즈 하스피털, 인크. 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법
RU2019104421A (ru) 2013-11-13 2019-04-17 Вертекс Фармасьютикалз Инкорпорейтед Способы получения ингибиторов репликации вирусов гриппа
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
CN106727556B (zh) * 2016-11-30 2017-10-20 鑫喆喆 一种治疗脑损伤的药物组合物
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
EP3837352A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895625A (en) * 1957-12-27 1962-05-02 Hoechst Ag New benzene-sulphonyl benzyl-ureas and process of preparing them
ES474449A1 (es) * 1978-10-23 1979-05-01 Invest Tecnica Aplicada Procedimiento de obtencion de ureas y tioureas con actividad farmacologica.
DE3371508D1 (en) * 1983-01-24 1987-06-19 Duphar Int Res Benzoylurea compounds, and pesticidal and pharmaceutical compositions comprising same
JPH10182588A (ja) * 1996-10-30 1998-07-07 Ss Pharmaceut Co Ltd 置換ベンジル尿素誘導体及びこれを含有する医薬
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
DE69806042T2 (de) * 1997-11-07 2003-01-23 Schering Corp Phenylalkyl imidazole derivate als h3 rezeptor liganden
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
WO2001068569A2 (en) * 2000-03-14 2001-09-20 Smithkline Beecham Corporation Il-8 receptor antagonists
IL155174A0 (en) * 2000-10-02 2003-10-31 Reddy Us Therapeutics Inc Methods and compositions for the treatment of inflammatory diseases
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
WO2007017145A3 (en) 2007-04-26
SI1919465T1 (en) 2018-04-30
CA2616451A1 (en) 2007-02-15
CN101257900A (zh) 2008-09-03
EP1919465A2 (en) 2008-05-14
JP2009502846A (ja) 2009-01-29
HRP20180109T1 (hr) 2018-04-20
US20090124686A1 (en) 2009-05-14
NZ566380A (en) 2011-01-28
CN101257900B (zh) 2012-09-12
EP1749523A1 (en) 2007-02-07
BRPI0615968B1 (pt) 2023-10-03
HUE036844T2 (hu) 2018-08-28
NO341454B1 (no) 2017-11-13
WO2007017145A2 (en) 2007-02-15
DK1919465T3 (en) 2018-02-05
US8686042B2 (en) 2014-04-01
EP1919465B1 (en) 2017-12-27
AU2006278829B2 (en) 2012-03-29
IL189048A0 (en) 2008-08-07
BRPI0615968A2 (pt) 2011-05-31
JP5484726B2 (ja) 2014-05-07
KR20080031440A (ko) 2008-04-08
RU2449998C2 (ru) 2012-05-10
CY1119971T1 (el) 2018-12-12
ZA200800983B (en) 2009-07-29
AU2006278829A1 (en) 2007-02-15
HK1124761A1 (en) 2009-07-24
KR101471999B1 (ko) 2014-12-10
RU2008107733A (ru) 2009-09-10
IL189048A (en) 2017-04-30
PT1919465T (pt) 2018-03-07
NO20081052L (no) 2008-02-28
CA2616451C (en) 2015-01-20
ES2661326T3 (es) 2018-03-28
PL1919465T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
ZA200800983B (en) GSK-3 inhibitors
IL178125A0 (en) Gsk-3 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
PL2264043T3 (pl) Heterobifunkcyjne inhibitory pan-selektyny
PL2383271T3 (pl) Aminochinolony jako inhibitory GSK-3
IL190078A0 (en) Kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1971595A4 (en) CETP INHIBITORS
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
EP1973889A4 (en) CETP INHIBITORS
ZA200802867B (en) Fap inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
EP1906945A4 (en) HCV INHIBITORS
EP1926485A4 (en) HIF-INHIBITORS
SI1943243T1 (sl) Inhibotorji kinaz
ZA200805386B (en) MIF inhibitors
IL188850A0 (en) Cathepsin k inhibitors
EP1951053A4 (en) CETP INHIBITORS
GB0515327D0 (en) Comt inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
ZA200711069B (en) HCV inhibitors